SciLocyte Dosage/Direction for Use





Metro Drug
Full Prescribing Info
Dosage/Direction for Use
Cancer Patients Receiving Myelosuppressive Chemotherapy: The recommended starting dose of Recombinant G-CSF is 5 mcg/kg/day, administered as a single daily injection by SC bolus injection, by short IV infusion (15 to 30 minutes), or by continuous SC or continuous IV infusion. A CBC and platelet count should be obtained before instituting Recombinant G-CSF therapy, and monitored twice weekly during therapy. Doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle, according to the duration and severity of the ANC nadir.
Recombinant G-CSF should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Recombinant G-CSF should not be administered in the period 24 hours before the administration of chemotherapy.
Cancer Patients Receiving Bone Marrow Transplant: The recommended dose of Recombinant G-CSF following BMT is 10 mcg/kg/day given as an IV infusion of 4 or 24 hours, or as a continuous 24-hour SC infusion. For patients receiving BMT, the first dose of Recombinant G-CSF should be administered at least 24 hours after cytotoxic chemotherapy and at least 24 hours after bone marrow infusion.
Peripheral Blood Progenitor Cell Collection and Therapy in Cancer Patients: The recommended dose of Recombinant G-CSF for the mobilization of PBPC is 10 mcg/kg/day SC, either as a bolus or a continuous infusion. It is recommended that Recombinant G-CSF be given for at least 4 days before the first leukapheresis procedure and continued until the last leukapheresis.
Dilution: If required, Recombinant G-CSF may be diluted in 5% dextrose, Recombinant G-CSF diluted to concentrations between 5 and 15 mcg/mL should be protected from adsorption to plastic materials by the addition of Albumin (Human) to a final concentration of 2 mg/mL. When diluted in 5% dextrose or 5% dextrose plus Albumin (Human), Recombinant G-CSF is compatible with glass bottles, PVC and polyolefin in IV bags, and polypropylene syringes.
Dilution of Recombinant G-CSF to a final concentration of less than 5 mcg/mL is not recommended at any time.
Do not dilute with saline at any time; product may precipitate.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in